Design Therapeutics Inc
NASDAQ:DSGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.15
7.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Design Therapeutics Inc
Design Therapeutics Inc
Revenue
Design Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Design Therapeutics Inc
NASDAQ:DSGN
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Design Therapeutics Inc
Glance View
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.
See Also
What is Design Therapeutics Inc's Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Revenue amounts to 0 USD.
You don't have any saved screeners yet
